This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $215,311 to the University of Texas Health Science Center at Houston (UTHealth) to evaluate the preclinical efficacy of GPR56 antibody-drug conjugates (ADCs) and combination therapies for the treatment of triple-negative breast cancer (TNBC).
The key objectives are to: 1) generate GPR56 ADCs by attaching different cytotoxic drugs and evaluate their cell-killing efficacy in TNBC cell lines; 2) assess the toxicity and evaluate the efficacy of lead GPR56 ADCs in mouse models using TNBC cell lines and patient-derived tumors; and 3) test if GPR56 ADCs in combination with PARP inhibitors can enhance antitumor efficacy and prevent metastasis in a mouse mammary carcinoma model. This research aims to provide a preclinical evaluation of GPR56 ADCs as a novel targeted therapy, both as a stand-alone treatment and in combination with PARP inhibitors, for improving outcomes in TNBC patients who have limited targeted therapeutic options.
Generated 3/25/25, 5:11 AM